HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 452 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,380 | +1814.6% | 102,749 | +1389.3% | 0.01% | – |
| Q1 2024 | $281 | -92.7% | 6,899 | -93.2% | 0.00% | -100.0% |
| Q3 2023 | $3,866 | -100.0% | 101,211 | -62.7% | 0.01% | -68.8% |
| Q3 2022 | $10,740,000 | +53.3% | 271,615 | +70.6% | 0.02% | +60.0% |
| Q2 2022 | $7,005,000 | -58.6% | 159,201 | -61.7% | 0.01% | -52.4% |
| Q3 2021 | $16,929,000 | +916.1% | 416,140 | +556.4% | 0.02% | +600.0% |
| Q3 2020 | $1,666,000 | +397.3% | 63,400 | +407.9% | 0.00% | +200.0% |
| Q2 2020 | $335,000 | -82.1% | 12,484 | -88.0% | 0.00% | -80.0% |
| Q1 2020 | $1,873,000 | -72.6% | 104,097 | -73.0% | 0.01% | -68.8% |
| Q4 2019 | $6,848,000 | +305.7% | 386,241 | +254.9% | 0.02% | +300.0% |
| Q3 2019 | $1,688,000 | +61.2% | 108,846 | +67.3% | 0.00% | +100.0% |
| Q1 2019 | $1,047,000 | -88.9% | 65,055 | -86.5% | 0.00% | -90.9% |
| Q1 2018 | $9,437,000 | +7103.8% | 481,718 | +4622.7% | 0.02% | – |
| Q2 2017 | $131,000 | – | 10,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
| BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
| QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
| Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
| SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
| Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
| HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
| Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
| Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |